Oryzon Secures Vafidemstat Patent Allowances in Four Countries

Oryzon Genomics received decisions to grant vafidemstat patents in four markets, expanding protection for psychiatric and neurodevelopmental uses. South Korean and Philippine allowances cover non-aggressive borderline personality disorder symptoms, with protection expected through at least 2040, excluding potential extensions. New Zealand's allowance covers aggression and social withdrawal, with protection expected through at least 2038, excluding potential extensions or adjustments. Mexico's allowance covers certain non-aggressive autism spectrum disorder symptoms; once granted, protection runs through at least 2040, excluding potential extensions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein. (C)